SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Documenti analoghi

• Critical insights into the evolving drug‐approval process in China
  di: Mina Nikanjam, et al.
  Pubblicazione: (2024)
• The evolving landscape of tissue‐agnostic therapies in precision oncology
  di: Vivek Subbiah, et al.
  Pubblicazione: (2024)
• CircRNome‐wide characterisation reveals the promoting role of circAATF in anti‐PD‐L1 immunotherapy of gallbladder carcinoma
  di: Yueqi Wang, et al.
  Pubblicazione: (2024)
• BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment
  di: Hsin‐Yi Tseng, et al.
  Pubblicazione: (2024)
• Non‐IL‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA‐4 therapy
  di: Yujia Peng, et al.
  Pubblicazione: (2024)